BLAINJECTIONINJECTABLE
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
CIMERLI (ranibizumab-eqrn) by Novartis is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2022.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMERLI (ranibizumab-eqrn) is a biosimilar monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), approved in August 2022 for 13 retinal and ocular conditions including diabetic macular edema, age-related macular degeneration, and retinal vein occlusions. It works by binding VEGF to prevent abnormal blood vessel growth and reduce macular edema in the eye. The biosimilar offers a lower-cost alternative to the reference ranibizumab product in a competitive ophthalmology market.
$0.082BPart D
PeakEarly-stage biosimilar in peak commercial phase with modest Part D claims, suggesting nascent market penetration and a growing but resource-constrained commercial footprint.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
Started Jul 2010
241 enrolled
Diabetic Macular Edema
Career Relevance
CIMERLI roles focus on commercial execution and market penetration in a competitive, price-sensitive ophthalmology landscape; limited job openings reflect early-stage biosimilar phase and modest Part D claim volume. Working on this product offers exposure to biosimilar launch strategy, payer negotiations, and competitive positioning in a niche but growing therapeutic area.
Brand Manager
Worked on CIMERLI at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.